Vigilant Biosciences is a leading innovator and developer of solutions that aid in the early detection and intervention of cancer. Our point-of-care and lab-based solutions are simple, accurate and cost-effective, empowering healthcare practitioners to improve potential outcomes through earlier intervention. The Vigilant Biosciences Scientific Advisory Board comprises of distinguished thought leaders and clinical advocates across fields of head and neck surgery, oncology, and oral medicine united in improving early detection and intervention for better outcomes.
Vigilant Biosciences products are based on advanced patented technology, including an innovative methodology for measuring total protein levels and assessing the level of tumor-initiating and stem cell-associated biomarker CD44 that, together with other clinical factors, can aid clinicians in the early detection and intervention of oral cancer. These clinically validated tests enable early and accurate detection of oral cancer, potentially even before visual or physical indicators. This foundational science leverages nearly two decades of clinical research conducted by Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.